Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares of the company’s stock, valued at $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, December 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.32, for a total value of $32,928.00.
• On Thursday, November 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $87.27, for a total transaction of $34,908.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded up $2.75 during mid-day trading on Wednesday, reaching $85.03. The company’s stock had a trading volume of 522,754 shares, compared to its average volume of 634,106. The stock has a 50-day moving average of $82.37 and a two-hundred day moving average of $83.54. The stock has a market capitalization of $1.91 billion, a P/E ratio of 52.17 and a beta of 0.51. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals, Inc. has a 1-year low of $54.10 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. increased its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals in the second quarter valued at $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ANIP shares. JPMorgan Chase & Co. lifted their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Barclays began coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price on the stock. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, Guggenheim increased their price target on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.14.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.